Memasolv (Memantine Hydrochloride)

Memantine works by binding to the NMDA‑type glutamate receptor as a non‑competitive antagonist. This blocks excessive calcium entry into neurons that occurs during prolonged glutamate stimulation, reducing excitotoxic damage. By moderating this pathway, memantine helps preserve neuronal function and may slow the progression of cognitive decline associated with Alzheimer’s disease.

The dosing regimen for Memasolv is determined by the prescribing clinician based on the individual’s clinical condition, renal function, and tolerability. Physicians typically start with a low dose and may titrate upward to the target maintenance dose, but the exact amount and schedule should be obtained from the prescriber’s instructions.

Safety data for memantine hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Memasolv, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

The primary alternative to memantine is the acetylcholinesterase inhibitor class, such as donepezil. While acetylcholinesterase inhibitors increase cholinergic activity, memantine modulates glutamatergic signaling. Both aim to improve cognition, but they have different mechanisms, side‑effect profiles, and may be used together in some treatment regimens to achieve complementary benefits.

Memasolv should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat, and direct sunlight. Do not store in bathrooms or near kitchen appliances, and keep out of reach of children.

Memasolv is taken orally, usually with or without food, as a whole tablet that should be swallowed with a glass of water. Patients should follow the prescriber’s dosing schedule, avoid crushing or chewing the tablet unless specifically instructed, and maintain consistent timing to help achieve stable plasma levels.

The most serious adverse reactions reported with memantine include seizures, severe allergic responses such as anaphylaxis, and cardiac arrhythmias. Patients experiencing sudden convulsions, rash with swelling, difficulty breathing, or irregular heartbeats should seek immediate medical attention. Regular monitoring is advised for individuals with pre‑existing neurological or cardiac conditions.

Memasolv is contraindicated in patients with known hypersensitivity to memantine hydrochloride or any of the tablet excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists. Pregnant or nursing women should only use the drug when clearly indicated by a physician.